原发性肝细胞癌体部立体定向放疗的疗效及安全性

近年来,随着肿瘤放疗技术进展,原发性肝细胞癌(hepatocellular carcinoma,HCC)的放疗引起越来越多的关注,越来越多的证据也表明其较好的疗效。其中,体部立体定向放疗(stereotactic body radiation therapy,SBRT)对于不适合一线手术或经皮射频消融技术的HCC患者,在提高局部控制率方面发挥了重要作用。SBRT的研究已经开展了很多,也获得了明确的疗效。但关于恰当治疗适应证,合理剂量分割等方面的研究仍有限。本文综述SBRT对于不可手术的HCC患者的有效性、安全性、适应证和剂量分割模式。

Efficacy and safety of stereotactic body radiation therapy for hepatocellular carcinoma

In recent years, with the progress of tumor radiotherapy, radiotherapy of primary hepatocellular carcinoma (HCC) has attracted more and more attention, and more and more evidences show that it has a good therapeutic effect. SBRT has been critical in improving local control or potential cure in liver lesions not amenable to first-line surgical resection or radiofrequency ablation. Active investigations of SBRT have recently started, yielding promising local control rates. However, the researches on optimal treatment indications, doses, and methods remain limited. Herein, this review discussed the emerging role of SBRT as current indications, optimal doses, efficacy and safety in non-surgical patients with primary HCC.